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Abstract 21 
Staphylococcus epidermidis has emerged as an important opportunistic pathogen causing 22 
orthopedic device-related infections (ODRIs). This study investigated the association of 23 
genome variation and phenotypic features of the infecting S. epidermidis isolate with the 24 
clinical outcome of the infected patient. S. epidermidis isolates were collected from 104 25 
patients with ODRI. Their clinical outcome was evaluated, after an average of 26 months, as 26 
either "cured" or "not cured". The isolates were tested for antibiotic susceptibility and biofilm 27 
formation. Whole genome sequencing was performed on all isolates and genomic variation 28 
was related to features associated with "cured" and "not cured". Strong biofilm formation and 29 
aminoglycoside resistance were associated with a "not cured" outcome (p = 0.031 and p < 30 
0.001, respectively). Based on gene-by-gene analysis, some accessory genes were more 31 
prevalent in isolates from the “not cured” group. These included: the biofilm-associated bhp 32 
gene; the antiseptic resistance qacA gene, the cassette chromosome recombinase encoding 33 
genes ccrA and ccrB and IS256-like transposase. This study identifies biofilm formation and 34 
antibiotic resistance as associated with poor outcome in S. epidermidis ODRI. Whole genome 35 
sequencing identified specific genes associated with a "not cured" outcome that should be 36 
validated in future studies. 37 
Keywords. Staphylococcus epidermidis; MRSE; virulence factors; antibiotic resistance; 38 
genotype; phenotype; orthopedic device-related infections.
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40 
Introduction 41 
Staphylococcus epidermidis is a common member of the human skin microflora, predominant 42 
in moist sites such as nares or fossae, and sebaceous areas such as the facial skin. With the 43 
advent of implanted and indwelling medical devices, S. epidermidis has emerged as a 44 
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prominent cause of nosocomial and device-associated infections (1, 2). The microorganism’s 45 
ability to switch from a commensal to pathogenic lifestyle is facilitated by its ability to rapidly 46 
attach to, and form biofilms upon, medical devices. In the case of orthopedic device-related 47 
infections (ODRI), S. epidermidis accounts for up to 43% of cases and is second only to S. 48 
aureus as the most prevalent causative organism (1, 2).  49 
Molecular epidemiological studies have begun to reveal information on both population 50 
structure and genetic diversity within S. epidermidis populations (3-5). The complete S. 51 
epidermidis genome is estimated at approximately 2.5 Mb and comprises 80% core genes and 52 
20% variable genes (3, 4, 6). Three distinct phylogenetic groups (clades) are evident in the 53 
population structure of S. epidermidis (3, 4, 6), with at least nine globally disseminated clonal 54 
complex lineages. The most common clonal complex (CC2) contains one particularly 55 
prominent sequence type: ST2 (32% of all isolates) (5, 7).  56 
In an attempt to identify the features that enable invasive infection in S. epidermidis, a number 57 
of studies have searched for features that may distinguish invasive from commensal S. 58 
epidermidis isolates on a genotypic and phenotypic level. Such studies have identified 59 
features such as IS256, folate dehydrogenase, copper remediation genes to be more common 60 
amongst invasive isolates (3, 6, 8, 9). However, clear separation between the two has proven 61 
difficult (9-11), perhaps indicating that the ability to invade the host and the ability to 62 
colonize it do not require significantly different genetically-encoded features. One possibility, 63 
that has not been explored to date however, is whether the genome/phenotype of the invasive 64 
isolates dictates the ultimate course of an infection i.e. whether the patient eventually has a 65 
successful treatment outcome, or a failed treatment outcome.  66 
In the present study, S. epidermidis isolates were prospectively collected from patients with 67 
ODRI and were assigned a clinical outcome (either "cured" or "not cured") after an extended 68 
patient follow-up (FUP). Clinical outcome was then related to genome variation and 69 
phenotypes believed to be important for S. epidermidis virulence.  70 
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 71 
Results 72 
Patient outcome and clinical parameters 73 
A total of 104 patients with S. epidermidis ODRI were included in this study, with complete 74 
demographic information shown in Table 1. The lower extremity cohort (70 patients) included 75 
only those patients with infection of the hip, knee and upper ankle joints as well as femur, 76 
tibia and fibula. The majority of patients of the complete cohort study (n = 85, 81.7%) were 77 
considered to have had a "cured" clinical outcome at FUP.  78 
Those considered to have a "not cured" clinical outcome at FUP were statistically more likely 79 
to have had multiple revision surgeries in comparison with "cured" outcome isolates (p < 80 
0.067) (Table 2). There was no association between outcome and any of the other monitored 81 
parameters such as diabetes, chronic immunosuppression or obesity (Table 2). 82 
 83 
Patient outcome and phenotypic properties of isolates 84 
Antibiotic susceptibility. Antibiotic susceptibility testing of the 104 S. epidermidis isolates 85 
found 74% (77/104) to be multiple resistant isolates and 67.3% (70/104) were resistant to 86 
methicillin (Table 1). Rifampicin resistance was also observed in 19.2% (20/104) of the 87 
isolates, which is notable due to the critical role of this antibiotic in treating ODRI. Resistance 88 
to aminoglycosides had a statistically significant influence on a "not cured" clinical outcome 89 
(p = 0.001; Table 3). Further antibiotic resistance (including resistance to aminoglycosides) 90 
had no statistically significant influence on any of the other prognostic parameters such as 91 
chronic or acute ODRI. Although isolates from the group of chronic ODRIs were more often 92 
resistant to aminoglycosides than isolates from the acute ODRI group (42.7% of versus 31%), 93 
this was not statistically significant (p = 0.276). Furthermore, multidrug-resistance also 94 
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showed no statistically significant difference between chronic and acute ODRIs (73.3% 95 
versus 75.9%). 96 
Biofilm formation. As shown in Table 1, 70.2% (73/104) of the isolates formed a biofilm in 97 
vitro. The ability to form biofilm was subdivided into weak biofilm-formers (37.5% (39/104) 98 
of the isolates), intermediate biofilm-formers (21.2%, 22/104) and strong biofilm-formers 99 
(11.5%, 12/104). The remaining isolates (29.8%, 31/104) were unable to form a biofilm under 100 
our in vitro conditions. A statistically significant association between biofilm forming ability 101 
and clinical "cured" versus "not cured" outcome was noted for the lower extremity cohort (p = 102 
0.031; Table 3). Strong biofilm forming ability also resulted in the highest percentage of "not 103 
cured" outcome for the complete cohort (33.3%, p = 0.059; Table 3). However, the strength of 104 
biofilm formation had no statistically significant influence on any of the prognostic variables 105 
such as multiple revision surgery. 106 
A description of biofilm-associated genes and relative presence with respect to in vitro 107 
biofilm forming ability is shown in Table 4. Among strong biofilm forming isolates the 108 
intercellular adhesion (icaA) gene was more prevalent (83.3%) than the accumulation-109 
associated protein encoding aap (8.3%), the bhp (cell wall associated biofilm protein) (16.7%) 110 
and the embp (extracellular matrix-binding protein) (66.7%). 111 
 112 
Patient outcome and pathogen genome variation 113 
Relationship between virulence associated genes and patient outcome. The 104 genomes 114 
were analyzed for the presence of a selection of genes previously described as virulence 115 
factors in S. epidermidis (Fig 1) (12-14). Within the population as a whole (i.e. "cured" and 116 
"not cured"-outcome isolates), aae (vitronectin), gehC (lipase), gehD (lipase), hlb (β-117 
hemolysin), sesB (S. epidermidis surface protein) and sesC (S. epidermidis surface protein) 118 
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were present in all 104 isolates. The methicillin resistance gene, mecA was carried by 68.3% 119 
of the isolates, whereby 69/70 of the phenotypically confirmed MRSE and 2/34 120 
phenotypically confirmed MSSE possessed this gene. Fig 1 also shows the distribution of the 121 
known virulence genes between the 2 clinical outcome groups ("cured" and "not cured"). A 122 
trend for the presence of aminoglycoside resistance gene, aacA (aac(6`)-aph(2")) and mecA 123 
on "not cured" outcome (p = 0.076 and p = 0.099, respectively) was observed. In addition, the 124 
presence of biofilm-associated bhp was statistically significantly associated with a "not cured" 125 
clinical outcome in the lower extremity cohort (p = 0.023). 126 
 127 
Accessory gene regulator (agr)-types. Overall agr-type I was the most prevalent type 128 
(38.5%, 40/104) among the isolates, followed by agr-type III (36.5%, 38/104). The 129 
distribution of the 3 different agr-types within the "cured" and "not cured" outcome groups 130 
are shown in Table 5, however there were no statistically significant differences (p ≥ 0.05). 131 
The only parameter associated with agr-type was acute infection (Table 5). All other clinical 132 
parameters were not statistically associated with agr-type. 133 
 134 
Multi-locus sequence typing (MLST).Within the 104 isolates, 21 different Sequence Types 135 
(STs) were identified based on the 7 loci scheme for S. epidermidis (15) using the build-in 136 
MLST function of BIGSdb, linked with pubMLST databases (4) (Table 6). Thirty isolates 137 
could not be assigned to any known ST. While the majority of the ST2 (13/18; 72.2%) and 138 
ST5 (16/18; 88.9%) isolates were associated with "cured" outcome, all ST57 (2/2; 100%), 139 
ST89 (1/1; 100%) and S110 (1/1; 100%) were associated with a "not cured" outcome (Table 140 
6). However, more isolates would be needed to draw statistical conclusions. The identified 141 
STs belonged to previously described 7-locus MLST clonal complexes (CC) of which the 142 
largest was CC2 (65/104; 62.5%) (4) (Table 6).  143 
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 144 
Patient outcome and accessory genomes. Further evaluation of the relative presence of 145 
accessory genes that were more prevalent in the "not cured" outcome group than in the 146 
"cured" outcome group is shown in Table 7. S. epidermidis isolates from the "not cured" 147 
outcome group carried the antiseptic resistance coding gene qacA at a statistically significant 148 
higher percentage than isolates from the "cured" outcome group (89.5% vs 27.1%; p = 0.023). 149 
Furthermore, the presence of the cassette chromosome recombinase encoding genes ccrA and 150 
ccrB (89.5% vs. 23.6%and 89.5% vs. 24.7%; p = 0.042 and p = 0.034, respectively) was 151 
significantly associated with the "not cured" isolate genomes.  152 
 153 
Core and accessory genome analysis. A pan-genome of all study isolates was used to 154 
compare the genomes of the 104 clinical S. epidermidis isolates. ClonalFrame was used to 155 
construct ancestral genealogies, free from recombination. In order to run ClonalFrame a 156 
stringent approach to select core genes based on presence in 100 % of the 104 isolates was 157 
applied. This resulted in a reduced core genome consisting of 123 non-truncated genes. S. 158 
epidermidis isolates clustered into 3 clades (Fig 2), with 86% of isolates (89/104) in clade A, 159 
9.6% (10/104 isolates) in clade B and 4.8% (5/104 isolates) in clade C (Fig 2A).  160 
Comparing patient outcome between the clades, a trend was observed between clade A and B. 161 
Clade B consisted of a comparatively higher percentage of "not cured" outcome isolates 162 
(40%, 4/10) than clade A carrying 15.7% (14/89, Fig 2A+C). However, this trend did not 163 
quite reach statistical significance (p = 0.08; Fisher`s exact test). Only 1/5 (20%) Clade C 164 
isolates belonged to the "not cured" outcome group, although the low numbers of isolates 165 
precluded reliable statistical analysis (Fig 2B+D). Furthermore, clade B isolates also 166 
contained a higher percentage of moderate/strong biofilm forming isolates than clade A 167 
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isolates (40% versus 31.5%) (Fig 3A+C). In addition, the majority of clade B isolates (80%) 168 
belonged to CC2 while clade A possessed only 60.7% CC2 isolates (data not shown).  169 
Clinical outcome, biofilm formation and antibiotic resistance phenotypes were homogeneous 170 
compared to the clonal frame (p ≥ 0.05). In addition, the permutation test revealed a strong 171 
association between lineage and biofilm formation (p ≤ 0.0001), resistance to methicillin (p = 172 
0.0002), quinolones (p = 0.0055), erythromycin (p < 0.00001), clindamycin (p < 0.00001), 173 
tetracycline (p < 0.00001), trimethoprim/sulfonamide (p = 0.02), and fusidic acid (p < 174 
0.00001). However, there was no association between lineage and outcome (p = 0.09) or 175 
resistance to penicillin (p = 1), aminoglycosides (p = 0.3798), fosfomycin (p = 0.053), and 176 
rifampicin (p = 0.151).  177 
 178 
Discussion 179 
S. epidermidis is a commensal microorganism that is also a frequent agent of ODRI (6, 8, 16, 180 
17). However, little is known about the impact that genotypic and phenotypic features of the 181 
infecting pathogen can have on treatment outcome (3, 6, 8, 9). This prospective study was 182 
designed to test the hypothesis that treatment outcome in patients with S. epidermidis ODRI 183 
may be influenced by phenotypic or genotypic features of the infecting pathogen. Against a 184 
background of scientific studies searching for features that distinguish commensal from 185 
invasive isolates (3, 6, 8-11), or for host factors that have an influence on patient outcome (8, 186 
18), this study advances this line of investigation by looking for bacteria-retained features that 187 
distinguish infections that result in poor treatment outcome. After prospectively collecting 188 
104 patients, with an average 2-year follow-up (FUP), and subjecting infecting pathogens to 189 
genome sequencing and a number of phenotypic assays, we have identified a number of 190 
features associated with poor treatment outcome. Those features include biofilm formation, 191 
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aminoglycoside resistance, the cassette chromosome recombinase encoding genes ccrA and 192 
ccrB, IS256-like and plasmid-borne qacA gene, as well as the biofilm-associated bhp gene. 193 
Adhesion to and biofilm formation upon biomaterial substrates are widely believed to be the 194 
primary virulence factor enabling invasive S. epidermidis ODRI (6, 8, 16, 17, 19). The data 195 
from our study supports this by revealing that a "not cured" clinical outcome was significantly 196 
associated with an increased ability to form biofilm in vitro (p = 0.031). Genomic analysis on 197 
the known biofilm-associated genes such as icaA, aap, bhp or embp, revealed that the only 198 
such gene found to be significantly associated with a "not cured" outcome was bhp in the 199 
lower extremity cohort (p = 0.023). Interestingly, bhp was most prevalent in the weak 200 
biofilm-forming isolates (52.7%) indicating that it's role may not be directly linked with 201 
biofilm forming ability, at least in vitro. Bhp has been reported to promote primary attachment 202 
to abiotic surfaces as well as intercellular adhesion during biofilm formation (20, 21). Thus, 203 
this protein might be important for rapid attachment to the implant rather than the amount of 204 
biofilm formed by the isolate per se. A rapid attachment clearly may be significant for early 205 
establishment of biofilm in vivo in "the race for the surface". This may partially explain its 206 
association with poor treatment outcome, despite the lack of association with in vitro biofilm 207 
forming ability.  208 
Antibiotic resistance is a second key challenge in treatment of ODRI. Previous studies have 209 
suggested that methicillin resistance is associated with a worse treatment outcome in 210 
staphylococcal ODRIs (22-24), although a number of studies have provided contrasting 211 
findings (8, 25, 26). Methicillin resistance is due to the mecA gene. In the present study, 212 
resistance to methicillin showed a trend for a "not cured" patient outcome (p = 0.082 based on 213 
phenotypic analysis, and p = 0.099 for presence of mecA gene), supporting previously 214 
reported trends (22-24). Furthermore, the chromosome recombinase A and B encoding genes 215 
ccrB and ccrA were significantly more prevalent in "not cured" clinical outcome isolates 216 
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(89.5% vs 65.8% and 89.5% vs 64.7%; p = 0.042 and p = 0.034, respectively). These two 217 
genes are responsible for the chromosomal insertion of the genetic element called 218 
staphylococcal cassette chromosome mec (SCCmec). The SCCmec mobile genetic island 219 
contains the mec gene complex including the methicillin resistance gene mecA. In this study 220 
91.8% of the ccrA/ccrB positive isolates possessed the mecA gene indicative for the presence 221 
of the mobile element SCCmec. Of those 67 ccrA/ccrB/mecA positive isolates, only 2 were 222 
not phenotypically resistant to methicillin, which might be due to mutations in the mecA gene. 223 
The 6 ccrA+/ccrB+ but mecA negative isolates were not phenotypically resistant to methicillin 224 
indicative of an absent SCCmec mobile element. 225 
A second antibiotic class pertinent to the treatment of ODRIs is the aminoglycosides 226 
(including gentamicin and tobramycin), which are commonly used in antibiotic loaded bone 227 
cement (2, 16, 19, 27). Resistance to aminoglycosides in S. epidermidis isolated from patients 228 
with ODRI typically ranges from 40-65% (19, 27). In this study, 39.4% of the isolates were 229 
resistant to gentamicin/aminoglycoside and we observed an association between the “not 230 
cured” outcome and being phenotypically resistant to aminoglycosides (p = 0.001). The 231 
majority of the aminoglycoside resistant isolates (65.8 %) carried the aacA (aac(6`)-aph(2") 232 
gene that confers resistance to all aminoglycosides. This gene was also observed in a higher 233 
prevalence in the "not cured" group (42.1% versus 22.4% in "cured"; p = 0.076). This 234 
correlates well with other studies in terms of prevalence of the aacA (aac(6`)-aph(2") gene 235 
amongst aminoglycoside resistant isolates ranging between 40-92% (16, 28, 29), although 236 
how this impacted upon treatment outcome was not described for these other studies.  237 
Our data also revealed that the antiseptic gene (quaternary ammonium compound) qacA gene 238 
was statistically more prevalent in the "not cured" outcome group (p = 0.023). The qacA gene 239 
is a plasmid-borne gene (pSK1 family plasmids) that confers resistance to antiseptics and 240 
disinfectants such as cetrimide, benzalkonium chloride and chlorhexidine (30-32). Our 241 
observation that the qacA gene was present in 67.3% of isolates (89.5% of “not cured” 242 
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isolates) within the complete cohort seems enriched compared to other studies for clinical 243 
(47%-52%) and commensal (25%) S. epidermidis isolates (31, 32). Despite relatively high 244 
presence in our collection and a moderate number of "not cured" isolates, there is some 245 
statistical significance to associate presence of this gene with a poor treatment outcome. Qac 246 
proteins are efflux pumps that not only protect bacteria from a variety of toxic substances but 247 
also from fluoroquinolones and β–lactams (30-32). The acquisition of such a gene/plasmid 248 
possibly from antiseptic usage within the hospital clearly provides the bacteria a survival 249 
advantage, especially in a clinical environment. Such resistant pathogens are therefore not 250 
only more difficult to clean within the hospital environment, but as we show, are also 251 
associated with a poor treatment outcome.  252 
In addition, the IS256-like transposase was more frequently present in "not cured" clinical 253 
outcome isolates than in "cured" outcome isolates (57.9% versus 36.5%; p = 0.085). Previous 254 
studies have described an association between the presence of the IS256 element, the aac(6`)-255 
aph(2") gene (33, 34), the icaADBC operon and the ability to form biofilm (11, 35, 36). 256 
Furthermore, IS256 has been suggested as molecular marker for the molecular typing and 257 
identification of nosocomial, invasive S. epidermidis isolates (9-11, 36). This study provides 258 
further evidence that IS256 is not only "enriched" within invasive isolates, but is also more 259 
prevalent in isolates with a poor treatment outcome. The increased prevalence in the "not 260 
cured" group indicates it is not a marker for infection, but rather potentially one for poor 261 
outcome however this warrants further study with a larger set of isolates. 262 
Previous genealogical reconstruction studies of S. epidermidis have shown that isolates 263 
clustered into 3 phylogenetic clades (4, 6), which is consistent with the observation in this 264 
study. To date, no study has associated genotypes with clinical outcomes in ODRI. In this 265 
study, a higher number of "not cured" outcome isolates where found in clade B compared to 266 
clade A and C. Clade B was also the lineage to have the strongest biofilm forming isolates. 267 
12 
 
Harris et al reported in their study an association between thick biofilm being 20% more 268 
common in CC2 isolates (6). In the present study, CC2 accounted for 80% of the 10 clade B 269 
isolates with 50% of them being responsible for moderate/strong biofilm formation. 270 
Furthermore, of these moderate/strong biofilm forming CC2 clade B isolates, 75% (3/4) 271 
resulted in a "not cured" outcome. This emphasizes that clade B CC2 isolates might be more 272 
likely to result in a poor clinical outcome. However, a greater number of isolates should be 273 
analyzed in a prospective manner in order to confirm this observation and determine whether 274 
it may be a prognostic molecular marker for poor treatment outcome.  275 
A limitation of this study was that only a single S. epidermidis colony from each patient was 276 
analyzed, although the infection could, at least in theory, be polyclonal. A previous study has 277 
shown that only a minority of prosthetic joint infections (28.5% (4/14 patients)) were due to 278 
polyclonal S. epidermidis strains (37). Any future studies should consider analyzing several 279 
colonies from each patient. Furthermore, the morphology of colonies was not recorded in this 280 
present study and so we do not know how many, if any, SCVs were present in the current 281 
collection, but this should be considered in future studies 282 
In general, SCVs present phenotypic features such as slow growth rate and small colony 283 
morphology (38-45). Additionally, SCVs are associated with increased biofilm-forming 284 
ability, antibiotic resistance and ability to internalize and persist in osteoblasts, all of which 285 
may contribute to prolonged treatment or even treatment failure (38-45). In contrast to S. 286 
aureus SCVs, very little information is available on S. epidermidis SCVs (38, 46). Only 287 
recently has the pathogenesis of PJIs been associated with S. epidermidis SCVs (38, 46, 47). 288 
Furthermore, SCV colonies from the same patient showed different appearance regarding 289 
growth rate, colony size and levels of gentamicin resistance when compared to each other 290 
(38). This highlights the importance of documenting and analyzing SCVs as they may 291 
influence treatment outcome.  292 
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Patients with a "not cured" clinical outcome were more likely to have had multiple revision 293 
surgeries in comparison with "cured" outcome (p<0.067), which is to be expected as revision 294 
surgery is a standard intervention for failed treatment We have considered the final outcome 295 
to be "cured" or "not cured" at follow-up, regardless of the treatment steps taken in the interim 296 
period. Therefore, even though multiple revision surgeries occurred, if the patient was free of 297 
infection at FUP, we considered it to be cured. Of course, the need for multiple revisions is 298 
possibly an indicator that the infection was a greater challenge to treat, however, in a large 299 
patient population such as this, there is often a need for multiple revision surgeries to advance 300 
the healing of the fracture, or replace the device, which may occur after infection has cleared, 301 
and so such patients have also had multiple surgeries.  302 
Overall, genome sequencing is not absolutely required to determine some of the features 303 
identified in this study as being associated with poor outcome. For example, routine antibiotic 304 
susceptibility testing and conventional in vitro biofilm assays are readily available to provide 305 
this information. Nevertheless, whole genome sequencing allowed us to test our hypothesis 306 
with greatest sensitivity, and also identified features that are less easily measurable in a 307 
clinical laboratory. Finally, it should be mentioned that the treatment of ODRI is achieved by 308 
antibiotic therapy and surgical removal of infected tissue. Therefore, the outcome of ODRI 309 
treatment will be influenced by these factors in addition to the host defenses and not solely 310 
upon the pathogen itself. The factors identified in this study therefore require prospective 311 
validation in further studies with larger patient cohorts in order to confirm their value as 312 
prognostic markers for ODRI treatment outcome. 313 
 314 
Materials and methods 315 
Ethics Statement 316 
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Institutional Review Board approval was obtained from the local ethical committee “Ethik-317 
Kommission der Bayerischen Landesärztekammer” under approval number 12063. The study 318 
was registered with https://clinicaltrials.gov with identifier NCT02640937. Only adult patients 319 
(> 18 years) were included in this study and all patients provided informed written consent 320 
prior to inclusion in the study.  321 
 322 
Staphylococcus epidermidis collection 323 
This was a prospective study performed between November 2011 and September 2013 at the 324 
BGU Murnau, Germany, a level-one trauma center with a high volume, 70-bed unit for septic 325 
and reconstructive surgery. The phenotypic investigation of biofilm formation of a subgroup 326 
of these isolates has been previously described (8), although no genome sequence data of 327 
these isolates has been previously published.  328 
Inclusion criteria comprised of patients treated for a confirmed S. epidermidis infection 329 
involving fracture fixation (FFI) or prosthetic joint infections (PJI). Most of the primary 330 
surgeries for fracture fixation or implantation of an endoprosthesis were performed in other 331 
hospitals. In cases where the patient developed an infection that was not treated/treatable at 332 
the primary center, the patients were transferred to the study site which has a specialized unit 333 
for ODRI treatment. Bacterial growth in at least two biopsies, collected at the site of interest 334 
in combination with nonunion, implant-loosening/failure or local and systemic signs 335 
suggesting a surgical site infection were requirements for the diagnosis of ODRI, as per 336 
hospital standard.  337 
In the previously described clinical study, patient data was analyzed as a complete study 338 
cohort, but also as a cohort including only patients with infections associated with the lower 339 
limb (8). This is because there are numerous outcome measures for the lower extremity that 340 
are not available for other anatomical locations. These outcome measures include the Lower 341 
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Extremity Functional Score (LEFS), the Short Form-12 (SF-12) score as well as leg length 342 
discrepancy (8). The remaining patients, not included in the lower extremity cohort, included 343 
patients with infections at other locations such as upper extremity, pelvis and spine (Table 1). 344 
At the first surgical procedure after enrolment, bone biopsies were taken from the interface 345 
between implant and affected bone. Samples were placed in a sterile container with 346 
thioglycollate liquid medium (bioMérieux, Hazelwood, MO, USA) and cultured for 10 days at 347 
37 °C. Any growth was inoculated onto a blood agar plate (bioMérieux, Hazelwood, MO, 348 
USA) for further growth and subsequent identification. All isolates were grown on Tryptone 349 
Soy Agar (TSA, Oxoid, Pratteln, Switzerland) and incubated overnight at 37 °C. A single 350 
colony was then taken and resuspended in 1 ml Tryptone Soy Broth (TSB, Oxoid, Pratteln, 351 
Switzerland) containing 20% vol/vol glycerol for long-term storage at -80 °C. Although 352 
colony morphology of culture positive samples was not described, we anticipate that SCV 353 
colonies had sufficient time to emerge under standard laboratory conditions, and are not likely 354 
to have been missed in the clinical routine. 355 
 356 
Clinical data collection 357 
Clinical data was collected from each enrolled patient. The following surgical parameters 358 
were documented: affected bone or joint; type of implant; time between implantation of the 359 
device and onset of symptoms; and whether the fracture was open or closed (PJIs excluded).  360 
Patients were assessed for treatment outcome after an average of 26 months follow-up (FUP). 361 
Patients were assigned to have had a "cured" or a "not cured" outcome at FUP. Patients had a 362 
"cured" clinical outcome if they were free of infection, surgical therapy and systemic 363 
antibiotic therapy ceased, and function of the affected joint or limb was restored. Patients 364 
were considered to have had a "not cured" clinical outcome if at least one of the above 365 
parameters was negative. Additional parameters were documented such as acute/non-acute 366 
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(chronic) infection (cut-off for onset of symptoms: six weeks), obesity (BMI ≥ 30kg/m2), 367 
diabetes, smoking, chronic immunosuppressive conditions (diabetes mellitus, chronic 368 
alcoholism, Child`s class C cirrhosis, neoplasia, transplantation, AIDS and steroid 369 
medication) and whether multiple revision surgeries were required during treatment.  370 
The clinical treatment strategies applied to these patients followed recent guidelines and 371 
recommendations, including guidance on antimicrobial stewardship. Therefore, treatment 372 
strategies differed between enrolled patients due to antibiotic resistance patterns, presence of 373 
implant (yes/no) and stage of treatment. The use of antibiotic loaded bone cement was not 374 
extracted from the patient records, however, in all cases of infection with a gentamicin 375 
resistant organism, any bone cement would have been loaded with vancomycin as the 376 
preferred alternative. Whether an implant was removed or retained was dependent upon the 377 
classification of the infection and the health status of the patient. In chronic infections, the 378 
implant was routinely removed in the first revision surgery whenever possible. In general, the 379 
implant was retained in acute infections if sufficient debridement was possible. 380 
Antibiotic susceptibility testing 381 
Antibiotic susceptibility to 28 antibiotics was determined using a Vitek2 machine 382 
(bioMérieux Vitek Inc., Hazelwood, MO, USA). The antibiotics tested were amikacin, 383 
ampicillin-sulbactam, cefotaxim, cefoxitin, cefuroxime, ciprofloxacin, clindamycin, 384 
daptomycin, erythromycin, fosfomycin, fusidic acid, gentamicin, levofloxacin, linezolid, 385 
mezlocillin, moxifloxacin, netilmicin, ofloxacin, oxacillin, penicillin, piperacillin, rifampicin, 386 
tetracycline, ticarcillin/clavulanate, tigecycline, tobramycin, trimethoprim-sulfamethoxazole 387 
and vancomycin. Multiple antibiotic resistance was defined according to the definitions of the 388 
European Committee of Antimicrobial Susceptibility Testing (EUCAST). Oxacillin resistance 389 
was considered definitive for methicillin resistance status.  390 
 391 
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Biofilm formation 392 
Biofilm formation was assayed as described previously (48, 49). Briefly, overnight cultures 393 
were grown in TSB and then sub-cultured in fresh TSB containing 1% glucose, to 394 
approximately 1x10
6
 CFU/ml. To achieve this, bacterial density was adjusted to a target 395 
optical density of known concentration using a Multiskan Go microplate reader (Thermo 396 
Scientific, Zürich, Switzerland). A total of 200 µl of the bacterial suspension was incubated in 397 
flat-bottomed 96-well tissue culture-treated polystyrene microtitre plates (Nuclon, Nunc A/S, 398 
Denmark) for 24 h at 37 °C. Plates were rinsed with phosphate-buffered saline (PBS, Sigma-399 
Aldrich, Buchs, Switzerland) and stained with 150 µl of Gram`s crystal violet solution 400 
(Sigma-Aldrich, Buchs, Switzerland). The dye bound to the attached cells was solubilized by 401 
addition of 150 µl of 95% ethanol. Optical density was measured as absorbance at 595 nm 402 
using the Multiskan Go microplate reader.  403 
All isolates were tested in triplicate in three independent experiments. Each microtitre plate 404 
also consisted of negative controls (wells without bacterial inoculation). The average OD 405 
value (ODa) was calculated for each isolate and the negative control. The results were 406 
evaluated using the scale described by Stepanovic et al. (49), whereby isolates may fall into 407 
the following four categories: no biofilm producer, weak biofilm producer, intermediate 408 
biofilm producer and strong biofilm producer. Based on the ODa values and the cut-off value 409 
(ODc), which is defined as three standard deviations (SD) above the mean OD of the negative 410 
control: ODc = average OD of negative control+(3xSD of negative control). The strength of 411 
the biofilm production of each isolate was calculated as following: ODa ≤ ODc = biofilm non-412 
producer; ODc < ODa ≤ 2xODc = weak biofilm producer; 2xODc < ODa ≤ 4xODc = 413 
intermediate biofilm producer and 4xODc < ODa = strong biofilm producer. S. epidermidis 414 
reference strain RP12 (ATCC 35983) was used as a control for strong biofilm production. 415 
 416 
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Genome sequencing and assembly 417 
S. epidermidis isolates were cultured on TSA plates at 37 °C for 24h. Single colony cultures 418 
were harvested and re-suspended in 3 ml of TSB medium to minimize clumping and 419 
incubated at 37 °C with overnight shaking. Chromosomal DNA was extracted using a Qiagen 420 
QiAmp DNA mini kit (Qiagen, Hilden, Germany) following the manufacturer`s protocol 421 
using 1 µg/ml lysostaphin (Sigma-Aldrich, Buchs, Switzerland) and 2 µg/ml lysozyme 422 
(Sigma-Aldrich, Buchs, Switzerland) to facilitate cell lysis. DNA was sequenced at the 423 
Swansea University Genome Centre using a MiSeq benchtop sequencer (Illumina, San Diego, 424 
CA, USA). Sequencing libraries were prepared using Nextera XT library preparation kits (v2) 425 
and paired-end 250 bp reads generated with the MiSeq run kit (v2). Short read data was 426 
assembled using a de novo assembly algorithm within Velvet software (version 1.2.08) (50). 427 
Overall, the average number of contiguous sequences (contigs) for all 104 genomes 428 
sequenced in this study was 439 which gave rise to an average total assembled genome size of 429 
2,436,856 bp. Short reads are available from the NCBI short read archive (SRA) associated 430 
with BioProject: PRJNA382527. Assembled genomes are also archived in the publicly 431 
accessible Staphylococcal Bacterial Isolate Genome Sequence database (BIGSdb; 432 
https://sheppardlab.com/resources/). 433 
Genomes are archived using a gene-by-gene approach for genome alignment and comparison 434 
supported by the BLAST algorithm (51). A reference pan-genome was constructed from the 435 
clinical isolate genomes (all collected as part of this study) and the reference S. epidermidis 436 
RP62A (ATCC 35984) and ATCC 12228 genomes (52). Putative gene function was assigned 437 
to genes in the reference pan-genome list using RAST (Rapid Annotations using Subsystem 438 
Technology)(53) and the SEED database (54) which were cross-referenced with the S. 439 
epidermidis RP62A (ATCC 35984) and ATCC 12228 reference genomes before removing 440 
duplicate genes. The BLAST algorithm was used to scan all genomes for gene orthologs at 441 
each locus in the reference pan-genome. An ortholog was defined as a reciprocal best hit of 442 
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the sequence with >70% nucleotide identity over at least 50% of the alignment length. 443 
MAFFT software (55) was used to align gene orthologs on a gene-by-gene basis, and these 444 
data concatenated into contiguous sequence for each isolate genome, including gaps. A core 445 
genome of 123 genes was defined based on gene presence in all isolates (100%).  446 
  447 
Estimating genealogies 448 
ClonalFrame infers the clonal relationship of bacteria and the chromosomal position of 449 
homologous recombination events that disrupt a clonal pattern of inheritance (56). A stringent 450 
approach was used to estimate a reduced core genome for construction of a genealogy using 451 
ClonalFrame (version 1.2) on concatenated sequences of 104 S. epidermidis genomes with 452 
100,000 iterations, half of which were discarded as burn-in. Substitution mutation and 453 
recombination regions were categorized from the output of ClonalFrame. The posterior 454 
probability of recombination and substitution at each site is calculated by ClonalFrame and 455 
recombination events were defined with a probability of recombination more than 75%, 456 
reaching 95% at any one site. The trees were visualized and annotated using MEGA6 (57).  457 
 458 
Statistical analysis 459 
Association amongst and between the clinical parameters, bacterial phenotypes, clades and 460 
presence/absence of genes were analyzed statistically using Chi-square test, Fisher`s exact 461 
test, Cochran-Armitage trend test or Kruskal-Wallis test as appropriate. Chi-square test was 462 
carried out to test the null hypothesis that the lineages are homogenous in their clinical 463 
outcome or resistance phenotypes. Permutation tests were performed to test the null 464 
hypothesis that there was no association between lineage and clinical outcome or resistance 465 
phenotype. Association between clinical outcome or antimicrobial resistance and lineage in 466 
the observed data was summarized by an association score. Statistical analyses were 467 
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performed using SAS software (Version 9.2; Cary, NC, USA) and SPSS (Version 10, IBM, 468 
USA) and level of significance set at p ≤ 0.05. 469 
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 667 
Figure legends 668 
Fig 1. Graph showing the percentage of genes present in the whole collection (black) and 669 
present in the two outcome groups. "Cured" outcome (dashed) and "not cured" outcome 670 
(grey), asterisk indicates statistically significance p ≤ 0.05. 671 
 672 
Fig 2. Population structure of S. epidermidis isolates constructed from 123 core genes and 673 
implemented in ClonalFrame. In (A) all 104 isolates of the complete cohort study and in (B) 674 
all 70 isolates of the lower extremity are labelled according to the clinical follow-up (FUP) 675 
outcome: "not cured" (black circle) and "cured" (open circle). (C) and (D) shows the 676 
percentage distribution of "cured" and "not cured" outcome in the three clades A, B, C with 677 
(C) showing the complete cohort and (D) the lower extremity cohort 678 
 679 
Fig 3. Population structure of S. epidermidis isolates constructed from 123 core genes and 680 
implemented in ClonalFrame. In (A) all 104 isolates of the complete cohort and in (B) of the 681 
lower extremity cohort are labelled according to the ability to form a biofilm: biofilm negative 682 
(open circles), weak biofilm (grey circles) and moderate to strong biofilm formers (black 683 
circles). (C) and (D) shows the percentage distribution of the strength of biofilm formation in 684 
the three clades A, B, C with (C) showing the complete cohort and (D) the lower extremity 685 
cohort. 686 
 687 
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Table 1. Patient health status, infection characteristics, bacteriology, clinical course and 688 
outcome.  689 
 Complete study 
cohort 
Lower extremity 
cohort 
Total, n (%)* 104 (100.0) 70 (100.0) 
Clinical course and infection outcome, n 
(%) 
  
 Multiple revision surgeries  89 (85.6) 68 (97.1) 
 Clinical outcome cured 85 (81.7) 53 (75.7) 
Health status n (%)   
 Obesity
1
 44 (42.3) 32 (45.7) 
 Smoking 28 (26.9) 17 (24.3) 
 Diabetes 14 (13.5) 8 (11.4) 
 Chronic immunosuppression 25 (24.0) 14 (20.0) 
Infection characteristics, n (%)   
 Infection after fracture fixation (FFI) 78 (75.0) 44 (62.9) 
 Prosthetic joint infections (PJI) 26 (25.0) 26 (37.1) 
 Acute infection 29 (27.9) 20 (28.6) 
 Closed facture
2
 53 (67.9) 25 (56.8) 
 Open fracture 25 (32.1) 19 (43.2) 
Type of implant, n (%)   
 Internal fixator 6 (5.8) 0 (0) 
 Prosthetic joint 26 (25.0) 26 (37.1) 
 Nail 23 (22.1) 20 (28.6) 
 Plate 40 (38.5) 22 (31.4) 
 Screw 8 (7.7) 2 (2.9) 
 K-wire 1 (1.0) 0 (0) 
Localization, n (%)   
Spine 6 (5.8) NA 
Upper extremity 7 (6.7) NA 
Pelvis 7 (6.7) NA 
Tibia 2 (1.9) NA 
Clavicle 3 (2.9) NA 
Hip joint 10 (9.6) 10 (14.3) 
Femur 7 (6.7) 7 (10.0) 
Knee joint 18 (17.3) 18 (25.7) 
Lower leg including upper ankle joint 35 (33.7) 35 (50.0) 
Lower ankle joint including foot 9 (8.7) NA 
Bacteriological evaluation, n (%)   
 Methicillin resistance 70 (67.3) 52 (74.3) 
 Multi-drug resistance 77 (74.0) 56 (80.0) 
 Biofilm formation, n (%)   
   Non 31 (29.8) 24 (34.3) 
   Weak 39 (37.5) 26 (37.1) 
   Intermediate 22 (21.2) 11 (15.7) 
   Strong  12 (11.5) 9 (12.9) 
*Single S. epidermidis isolate from each patient. 690 
1
Obesity defined as body mass index BMI > 30. 691 
2
PJI not included. 692 
NA: not applicable 693 
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Table 2. Association between prognostic factors and cure status for the complete study 694 
cohort. 695 
 Cured  
 No Yes  
 n (%) n (%) 
Odds ratio for 
cured
1 
(95%-
Confidence 
Interval) p-value 
Total number of patient* 19 (18.3) 85 (81.7)   
Infection type   0.92 
(0.30;2.86) 
1.000
†
 
FFI 14 (17.9) 64 (82.1)   
PJI 5 (19.2) 21 (80.8)   
Fracture   0.39 
(0.12;1.27) 
0.126
†
 
Closed 7 (13.2) 46 (86.8)   
Open 7 (28.0) 18 (72.0)   
Acute infection   1.56 
(0.44;7.08) 
0.463
††
 
No 15 (20.0) 60 (80.0)   
Yes 4 (13.8) 25 (86.2)   
Multiple-revision surgery   0.12 
(0.00;2.04) 
0.067
†
 
No 0 (0.0) 15 (100.0)   
Yes 19 (21.3) 70 (78.7)   
Obesity   0.78 
(0.25;2.42) 
0.621
††
 
No 10 (16.7) 50 (83.3)   
Yes 9 (20.5) 35 (79.5)   
Smoking   0.76 
(0.23;2.74) 
0.613
††
 
No 13 (17.1) 63 (82.9)   
Yes 6 (21.4) 22 (78.6)   
Diabetes   0.50 
(0.14;1.81) 
0.281
†
 
No 15 (16.7) 75 (83.3)   
Yes 4 (28.6) 10 (71.4)   
Chronic 
immunosuppression 
  0.46 
(0.16;1.34) 
0.233
†
 
No 12 (15.2) 67 (84.8)   
Yes 7 (28.0) 18 (72.0)   
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1
For calculation of odds ratios involving cells with 0 observations, the 0.5 zero-cell correction 696 
was applied. 697 
*Each patient had 1 S. epidermidis isolate. 698 
†Chi-Square test 699 
††Fishers exact test 700 
 701 
 702 
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Table 3: Association between bacterial phenotype and clinical cured status 703 
 
Complete cohort  
(n=104) 
Lower extremity cohort  
(n=70) 
 Cured  Cured   
 No Yes  No Yes   
 n (%) n (%) 
Odds ratio for cured 
(95%-Confidence 
Interval) p-value n (%) n (%) 
Odds ratio for cured 
(95%-Confidence 
Interval) p-value 
Biofilm formation    0.059
†††
    0.031
†††
 
No  3 (9.7) 28 (90.3)   3 (12.5) 21 (87.5)   
Weak  7 (17.9) 32 (82.1) 0.49 (0.08;2.43)  6 (23.1) 20 (76.9) 0.48 (0.07;2.64)  
Intermediate  5 (22.7) 17 (77.3) 0.36 (0.05;2.19)  4 (36.4) 7 (63.6) 0.25 (0.03;1.96)  
Strong  4 (33.3) 8 (66.7) 0.21 (0.03;1.62)  4 (44.4) 5 (55.6) 0.18 (0.02;1.51)  
Antibiotic resistance*         
Methicillin   0.33 (0.06;1.29) 0.082
††
   0.54 (0.14;2.16) 0.529
†
 
No 3 (8.8) 31 (91.2)   3 (16.7) 15 (83.3)   
Yes 16 (22.9) 54 (77.1)   14 (26.9) 38 (73.1)   
Aminoglycosides   0.17 (0.04;0.56) <.001
††
    0.051
††
 
No 5 (7.9) 58 (92.1)   5 (14.3) 30 (85.7) 0.32 (0.08;1.17)  
Yes 14 (34.1) 27 (65.9)   12 (34.3) 23 (65.7)   
*Not all antibiotic resistances are listed. Others tested showed no statistical significance. 704 
†Chi-Square test, ††Fishers exact test, ††† Cochran-Armitage Trend Test 705 
 706 
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 707 
Table 4. Biofilm-associated genes and biofilm formation. 708 
Presence of 
Biofilm-associated 
genes  
Complete cohort study (n=104) Lower cohort study (n=70) 
Strength of biofilm in vitro 
n; (%) 
Strength of biofilm in vitro 
n; (%) 
None 
(n=31) 
Weak 
(n=39) 
Intermediate 
(n=22) 
Strong 
(n=12) 
None 
(n=24) 
Weak 
(n=26) 
Intermediate 
(n=11) 
Strong 
(n=9) 
icaA 7 (22.6) 7 (18.0) 8 (36.4) 10 (83.3) 7 (29.2) 5 (19.2) 6 (54.5) 8 (88.9) 
aap 1 (3.2) 0 (0) 0 (0) 1 (8.3) 1 (4.2) 0 (0) 0 (0) 0 (0) 
bhp 7 (22.6) 10 (25.7) 0 (0) 2 (16.7) 4 (16.7) 9 (34.6) 0 (0) 1 (11.1) 
embp 28 (90.3) 31 (79.5) 15 (68.2) 8 (66.7) 21 (87.5) 20 (76.9) 6 (54.5) 6 (66.7) 
 709 
 710 
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Table 5. Association between the agr-types and clinical outcome.  711 
 agr-type
1
 p-value
$
 
Outcomes I II III  
 n (%) n (%) n (%)  
Clinical outcome    0.946 
Not cured 7 (36.8) 5 (26.3) 7 (36.8)  
Cured 33 (39.8) 19 (22.9) 31 (37.3)  
Acute Infection    0.002 
Non acute (chronic) 26 (35.1) 13 (17.6) 35 (47.3)  
Acute 14 (50.0) 11 (39.3) 3 (10.7)  
1 
Two isolates, not belonging to any of the 3 agr groups were excluded for statistical reasons. 712 
$
Chi-Square test 713 
 714 
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Table 6. MLST of the 104 clinical S. epidermidis isolates. 715 
ST
a
 CC
b
 No of isolates; 
n (%) 
Clinical outcome 
   “Cured” “Not cured” 
2 2 18 (17.3) 13 (72.2) 5 (27.8) 
5 2 18 (17.3) 16 (88.9) 2 (11.1) 
7 2 1 (1.0) 1 (100) 0 (0) 
23 2 4 (3.9) 4 (100) 0 (0) 
57 2 2 (1.9) 0 (0) 2 (100) 
59 2 6 (5.8) 5 (83.3) 1 (16.7) 
73 2 1 (1.0) 1 (100) 0 (0) 
83 2 1 (1.0) 1 (100) 0 (0) 
87 2 4 (3.9) 2 (50) 2 (50) 
88 2 1 (1.0) 1 (100) 0 (0) 
89 2 1 (1.0) 0 (0) 1 (100) 
130 2 6 (5.8) 6 (100) 0 (0) 
184 2 1 (1.0) 1 (100) 0 (0) 
384 2 1 (1.0) 1 (100) 0 (0) 
19 147 2 (1.9) 2 (100) 0 (0) 
32 S32 2 (1.9) 2 (100) 0 (0) 
110 S110 1 (1.0) 0 (0) 1 (100) 
167 S167 1 (1.0) 1 (100) 0 (0) 
297 S297 1 (1.0) 1 (100) 0 (0) 
490 S490 1 (1.0) 1 (100) 0 (0) 
528 S528 1 (1.0) 1 (100) 0 (0) 
n/a n/a 30 (28.9) 25 (83.3) 5 (16.7) 
total  104 (100) 85 19 
a
Sequence types determined using the built-in MLST function of BIGSdb, linked with 716 
pubMLST databases. Lack of information denotes the possible truncation of a corresponding 717 
MLST locus at the end of a contig. 718 
b
Clonal complexes were obtained from previously described data (Meric et al.2015). 719 
 720 
 721 
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Table 7. Relative over-representation of accessory genes in the "Not cured" outcome isolates (> 20% difference) 722 
Loci Description No. isolates 
"Not cured" 
(n = 19) 
Prevalence 
"Not cured" 
% 
No. isolates 
"cured" (n 
= 85) 
Prevalence 
"Cured"% 
Difference % 
"Not cured" vs 
"Cured" 
p-value 
SERP0915 IS256-like transposase 11 57.9 31 36.5 21.4 0.085 
SERP1222 Transposase 9 47.4 16 18.8 28.5 0.008 
SERP1586 Acetyltransferase, GNAT family 9 47.4 22 25.8 21.5 0.064 
SERP2498 Cassette chromosome recombinase A (ccrA) 17 89.5 56 65.8 23.6 0.042 
SERP2499 Cassette chromosome recombinase B (ccrB) 17 89.5 55 64.7 24.7 0.034 
id1043_1239 Hypothetical protein 10 52.6 25 29.4 23.3 0.053 
id1044_0888 Phage protein 8 42.1 15 17.6 24.5 0.02 
id1044_0895 Phage antirepressor protein 8 42.1 17 20 22.1 0.041 
id1044_1909 Antiseptic resistance protein QacA 17 89.5 53 62.4 27.1 0.023 
id1044_2610 unknown 8 42.1 15 17.6 24.5 0.02 
id1048_0369 Replication-associated protein 11 57.9 29 34.1 23.7 0.054 
id1632_0817 Zn-dependent hydroxyacylglutathione hydrolase 14 73.7 44 51.7 21.9 0.082 
 723 
 724 



